Evaxion Biotech (NASDAQ: EVAX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.330 | -0.250 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Evaxion Biotech (NASDAQ: EVAX) through any online brokerage.
Other companies in Evaxion Biotech’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Synaptogenix (NASDAQ:SNPX), Celyad Oncology (NASDAQ:CYAD), Brooklyn (NASDAQ:BTX) and Applied Genetic (NASDAQ:AGTC).
The latest price target for Evaxion Biotech (NASDAQ: EVAX) was reported by Oppenheimer on Tuesday, March 2, 2021. The analyst firm set a price target for 18.00 expecting EVAX to rise to within 12 months (a possible 862.57% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Evaxion Biotech (NASDAQ: EVAX) is $1.87 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for Evaxion Biotech.
Evaxion Biotech’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Evaxion Biotech.
Evaxion Biotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.